Remus Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Remus Pharmaceuticals has been growing earnings at an average annual rate of 147.6%, while the Healthcare industry saw earnings growing at 29.7% annually. Revenues have been growing at an average rate of 82.6% per year. Remus Pharmaceuticals's return on equity is 44.4%, and it has net margins of 18.8%.
Key information
147.6%
Earnings growth rate
142.5%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 82.6% |
| Return on equity | 44.4% |
| Net Margin | 18.8% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Remus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 451 | 85 | 55 | 0 |
| 31 Mar 22 | 247 | 34 | 34 | 0 |
| 31 Mar 21 | 188 | 10 | 30 | 0 |
| 31 Mar 20 | 124 | 8 | 31 | 0 |
Quality Earnings: REMUS has a high level of non-cash earnings.
Growing Profit Margin: REMUS's current net profit margins (18.8%) are higher than last year (13.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if REMUS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare REMUS's past year earnings growth to its 5-year average.
Earnings vs Industry: REMUS earnings growth over the past year (147.6%) exceeded the Healthcare industry 28%.
Return on Equity
High ROE: REMUS's Return on Equity (44.4%) is considered outstanding.